Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model
- 1.2k Downloads
The plasma concentration–time profile of a drug is essential to explain the relationship between the administered dose and the kinetics of drug action. However, in some cases such as in pre-clinical pharmacology or phase-III clinical studies where it is not always possible to collect all the required PK information, this relationship can be difficult to establish. In these circumstances several authors have proposed simple models that can analyse and simulate the kinetics of the drug action in the absence of PK data. The present work further develops and evaluates the performance of such an approach. A virtual compartment representing the biophase in which the concentration is in equilibrium with the observed effect is used to extract the (pharmaco)kinetic component from the pharmacodynamic data alone. Parameters of this model are the elimination rate constant from the virtual compartment (KDE), which describes the equilibrium between the rate of dose administration and the observed effect, and the second parameter, named EDK50 which is the apparent in vivo potency of the drug at steady state, analogous to the product of EC50, the pharmacodynamic potency, and clearance, the PK “potency” at steady state. Using population simulation and subsequent (blinded) analysis to evaluate this approach, it is demonstrated that the proposed model usually performs well and can be used for predictive simulations in drug development. However, there are several important limitations to this approach. For example, the investigated doses should extend from those producing responses well below the EC50 to those producing ones close to the maximum response, optimally reach steady state response and followed until the response returns to baseline. It is shown that large inter-individual variability on PK–PD parameters will produce biases as well as large imprecision on parameter estimates. It is also clear that extrapolations to dosage routes or schedules other than those used to estimate the parameters should be undertaken with great caution (e.g., in case of non-linearity or complex drug distribution). Consequently, it is advised to apply this approach only when the underlying structural PD and PK are well understood. In any case, K–PD model should definitively not be substituted for the gold standard PK–PD model when correct full model can and should be identified.
Keywordspopulation pharmacokinetic–phamacodynamic simulation kinetics of drug action dose-response-time-model K–PD model
Unable to display preview. Download preview PDF.
- 2.Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 29:358–371Google Scholar
- 14.Levy G. (1967) Kinetics of pharmacologic activity of succinylcholine in man. J. Pharm. Sci. 56:1657–1688Google Scholar
- 16.Van Rossum J.M. (1977) Kinetics of Drug Action. Springer Verlag, Berlin, Heidelberg, New YorkGoogle Scholar
- 17.Rowland M., Tozer T.N. (1980) Clinical Pharmacokinetics: Concepts and Applications, 1st edn. Lea & Febiger, PhiladelphiaGoogle Scholar
- 20.Bragg P., Fisher D.M., Shi J., Donati F., Meistelman C., Lau M., Sheiner L.B. (1994) Comparison of twitch depression of the adductor pollicis and the respiratory muscles. Pharmacodynamic modeling without plasma concentrations. Anesthesiology. 80:310–319Google Scholar
- 23.J. Gabrielsson and D. Weiner. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications. Swedish Pharmaceutical Press, 2000.Google Scholar
- 24.Beal S.L., Sheiner L.B. (1992) NONMEM User’s Guide, Part I. University of California at San Francisco, San FranciscoGoogle Scholar
- 25.P. Girard and F. Mentré. A comparison of estimation methods in non-linear mixed effects models using a blind analysis. PAGE 14 (2005) Abstr 834 [www.page-meeting.org/?abstract=834].Google Scholar
- 26.van Schaick E.A., de Greef H.J., Langemeijer M.W., Sheehan M.J., IJzerman A.P., Danhof M. (1997) Pharmacokinetic–pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N 6-(p-sulfophenyl) adenosine in rats. Br. J. Pharmacol. 122: 525–533PubMedCrossRefGoogle Scholar
- 27.P. Jacqmin. Modelling of kinetics of drug action without plasma concentrations, when and how? In M. Danhof, M. Karlsson, and R. J. Powell (eds.) Measurements and Kinetics of in vivo Drug Effects. LACDR, Leiden; 2002.Google Scholar
- 28.T. Goggin, P. Jacqmin, R. Gieschke, G. Pillai, E. Snoeck, P. Girard, and J. L. Steimer. Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug. PAGE 10 (2001) Abstr 180 [www.page-meeting.org/?abstract=180].Google Scholar